Decoy Therapeutics (DCOY) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on developing treatments for cancers with high unmet medical need, particularly those caused by dysregulated gene expression.

• Pipeline includes two small molecule drugs: SP-3164 (targeted protein degrader) and seclidemstat (SP-2577, targeted protein inhibitor), with potential applications in both liquid and solid tumors.

• Operates as a smaller reporting company, allowing for scaled disclosure and reduced reporting requirements under SEC rules.

Financial performance and metrics

• Audited financial statements for the two most recent fiscal years are presented, as permitted for smaller reporting companies.

• Independent auditors have included a going concern explanatory paragraph in their reports, indicating substantial doubt about the company's ability to continue as a going concern.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including working capital, capital expenditures, R&D, clinical trials, acquisitions, and investments.

• Additional details on use of proceeds will be provided in the applicable prospectus supplement for each offering.